# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹619 Cr** Q4 (+17.4% YoY) · **₹2,319 Cr** FY26 (+11.5% YoY) * **EBITDA Margin:** **15.2%** Q4 (+251 bps) · **12.4%** FY26 ## B. Revenue & Margin Drivers * **Operational Excellence:** Achieved record quarterly top-line performance through enhanced capacity utilization and cost optimization rather than price hikes alone. * **Mix & Pricing Dynamics:** Margin expansion was fueled by strong traction in non-Ibuprofen products and a slight uptick in finished goods pricing. * **Chemical Segment Recovery:** Management noted a significant improvement in Ethyl Acetate margins in early FY27 (April/May) compared to the preceding quarter. ## C. Profitability & Cost Structure * **Efficiency Gains:** Robust bottom-line growth was supported by disciplined execution and efficient working capital management despite global volatility. * **Rising Opex:** Employee expenses have doubled over two years to nearly **₹70 Cr**, driven by new plant commissioning, increased headcount, and variable pay provisions. * **Inventory Position:** Reported inventory of **₹371 Cr** reflects both rising raw material costs and stocks of self-manufactured products. ## D. Capital Allocation & Outlook * **Phased Expansion:** Future growth centers on a newly acquired **100-acre** land parcel, requiring an estimated annual investment of **₹200 Cr to ₹250 Cr**. * **Strategic Spending:** Planned capex is bifurcated into **60%** for direct growth activities and **40%** for infrastructure, automation, and land. * **Shareholder Returns:** The Board is currently prioritizing capital for high-growth projects over share buybacks to maximize long-term value. --- # 2. Manufacturing & Capacity ## A. Key Figures * **Pharma Capacity Utilization:** **90%** average (85%–95% range) for Ibuprofen, Metformin, Clopidogrel, and Fenofibrate * **Chemicals Capacity Utilization:** **98%–100%** for Acetic Anhydride and Ethyl Acetate * **Paracetamol Capacity:** **10,800 MT** total (expanded from 3,600 MT) · **55%** current utilization ## B. Utilization Rates & Outlook * **Chemical Segment Saturation:** Core chemical lines are operating at near-total capacity despite recent expansions, indicating a high-demand environment and limited immediate headroom. * **Paracetamol Ramp-up:** Following a significant tripling of capacity, utilization is expected to scale to **75%** in the current fiscal and reach full capacity by **FY 2028**. * **Ethyl Acetate Expansion:** Successfully increased output to **120,000 tons**, with the market immediately absorbing the new volume at peak utilization levels. ## C. Greenfield Expansion * **Strategic Land Acquisition:** Secured **100 acres** near Bhatinda Highway for a new multi-product site (Chemicals and APIs) to mirror the existing plant's success. * **Project Timeline:** Environmental clearance is already in place; management expects final regulatory approvals within **3–4 months** and project commencement within **4–8 quarters**. ## D. Automation Initiatives * **Efficiency Drivers:** The new paracetamol facility is fully automated, which is expected to drive down unit production costs as utilization rates climb. --- # 3. Product & Segment Performance ## A. Key Figures * **Ibuprofen Utilization:** **90% to 95%** capacity utilization * **Pharma Revenue Mix:** **62%** Ibuprofen · **38%** Non-Ibuprofen * **Global Demand Growth:** **3% to 4%** annually (Ibuprofen) ## B. Ibuprofen Portfolio * **Market Stabilization:** Demand has normalized following prior overstocking and competitive entries; management projects sustainable demand for the next **four to six quarters**. * **Global Leadership:** Maintained dominant market position through high capacity utilization and expects continued growth via export expansion and process improvements. * **Margin Outlook:** Management expresses high confidence in segment profitability over the near term, anticipating no significant margin pressures. ## C. Non-Ibuprofen APIs * **Diversification Momentum:** Healthy growth observed in Paracetamol and Metformin; portfolio expansion continues with the launch of **Minoxidil** and increased **Pantoprazole** capacity. * **Export Catalysts:** Possession of **CEP certification** for the entire non-Ibuprofen range is expected to accelerate export volumes in the current fiscal year. * **Revenue Potential:** While some APIs are commodities, specialized products like Clopidogrel and Fenofibrate are targeted to generate **INR 100 Cr to INR 150 Cr** within two years. ## D. Chemical Business * **Profitability Drivers:** Strong quarterly performance fueled by improved realizations in **Ethyl Acetate** and the commissioning of **Triacetin**. * **Operational Strategy:** Ethyl Acetate remains a 100% merchant-sale product; Triacetin provides entry into diverse high-value sectors including food, cosmetics, and cigarette filters. ## E. Product Pipeline * **Regulatory Scaling:** Focus is shifting toward scaling products that recently secured regulatory approvals across global markets following multi-year investment cycles. * **Strategic Filings:** Filed **ANDAs** for two to three additional products; approvals are structurally linked to the formulator’s application success. * **Disclosure Policy:** Management maintains a robust pipeline but adheres to a strict policy of announcing products only upon final production decisions. --- # 4. Geography & Market Mix ## A. Key Figures * **Export Reach:** **80+ countries** Global footprint (Europe, Brazil, LATAM) * **Ibuprofen Export Mix:** **45%** of total sales (Targeting continued growth) * **Non-Ibuprofen Export Mix:** **20%** Current share · **25%** FY2027 Target * **Regulated Market Exposure:** **25%** of non-ibuprofen exports ## B. Export Growth & Strategy * **Geographic Diversification:** Robust global presence with a strategic pivot toward Europe and developing nations to scale non-ibuprofen volumes. * **Product Mix Shift:** Management is aggressively targeting a higher export contribution for non-ibuprofen products, aiming for a **5% increase** in share by FY2027. * **Market Specifics:** European markets remain the primary destination for Ibuprofen; however, direct U.S. penetration is currently constrained by local manufacturing competition. ## C. Regulated Markets & Approvals * **Regulatory Momentum:** Secured U.S. FDA approvals for **Metformin and Fenofibrate** via the CEP pathway, bypassing the need for physical site inspections. * **Margin Optimization:** Active engagement with developed market clients to capture higher realizations, with **Clopidogrel** identified as a high-potential margin driver. * **Pricing Dynamics:** Convergence of U.S. and European generic pricing over the last two decades has neutralized historical premiums in the American market. * **Macro Tailwinds:** Anticipated demand surge from Western nations due to a multi-year decline in local API manufacturing investment. ## D. Domestic Demand & Customer Profile * **Local Market Strength:** Consistent upward trajectory in Indian API demand, which currently absorbs the vast majority of non-ibuprofen production. * **Client Quality:** Portfolio anchored by "A-grade" pharmaceutical entities, spanning innovators, large OTC players, and generic manufacturers. --- # 5. Supply Chain & Operations ## A. Key Figures * **Acetic Anhydride Captive Use:** **50% to 60%** of total production * **R&D Intensity:** **2% to 3%** of annual expenses ## B. Backward Integration & R&D * **Captive Consumption Strategy:** Significant internal utilization of Acetic Anhydride supports API backward integration, with surplus volumes sold externally. * **Process-Centric R&D:** Investment is focused on process validation for upcoming launches and optimizing existing product line efficiencies. ## C. Raw Material Sourcing & Disruptions * **Supply Chain Resilience:** Operations stabilized following a brief **one-week disruption** in crude-based chemicals and gas supplies from government refineries in March. * **China Dependency:** Critical starting materials for Metformin remain reliant on Chinese imports due to a total lack of domestic manufacturing alternatives in India. ## D. Import Substitution & Market Dynamics * **Strategic Triacetin Production:** Internal manufacturing of Triacetin is being leveraged for technological advantages and as a viable import substitute. * **Geopolitical & Regulatory Shifts:** Management is evaluating indigenization to counter China dependency and capitalize on shifting API demand resulting from stricter European environmental mandates. * **API Pipeline Constraints:** Despite broader R&D efforts, there are currently no active plans to launch new API-specific products aimed at substituting Chinese imports. --- # 6. Pricing & Regulatory Risks ## A. Input Cost Volatility * **Margin Stability:** Management anticipates stable margin performance for the **next one or two quarters**, as rising realizations are balanced by escalating input costs. * **Pricing Strategy:** Robust pass-through mechanisms are in place to offset raw material inflation; however, "abnormal gains" are restricted by a customer mix favoring direct consumers over traders. * **Realization Trends:** Broad-based price increases are being realized across the portfolio, with specific momentum in **Ibuprofen and Paracetamol** across domestic and export markets. * **Cost Drivers:** Significant raw material inflation and logistics disturbances intensified in **late March 2026**, though the price-to-cost spread remains relatively resilient. ## B. Geopolitical Disruptions * **External Headwinds:** Indirect exposure to the West India conflict and crude oil volatility is driving up logistics expenses and causing global shipping delays. ## C. Environmental Approvals * **Project Status:** Greenfield expansion has successfully secured **environmental approval**, with current on-site activity focused on foundational infrastructure while awaiting final regulatory clearances. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **15%** FY27 target (Mid-to-high teens) * **EBITDA Margin:** **12.4%** current (blended) · **14% – 14.5%** FY27 target · **16% – 18%** internal stretch goal * **Capex (Greenfield):** **₹1,200 Cr – ₹1,400 Cr** total outlay (4-5 years) · **₹200 Cr – ₹250 Cr** annual run-rate * **Employee Expenses:** **9% – 10%** of total revenue ## B. Revenue & Margin Outlook * **Growth Drivers:** Sustained double-digit top-line momentum underpinned by the **non-Ibuprofen portfolio**, improved capacity utilization, and operational efficiencies. * **Profitability Expansion:** Management targets a meaningful step-up in EBITDA margins for the upcoming year, prioritizing full-year stability over quarterly volatility. * **Segment Reporting:** Future guidance will treat Ibuprofen and non-Ibuprofen products as a **unified pharmaceutical segment** to streamline performance tracking. ## C. Capex & Capital Allocation * **Strategic Investment:** Multi-year greenfield expansion focused on the **pharmaceuticals segment**, with **₹200 Cr** earmarked specifically for FY27. * **Funding Profile:** Large-scale capital expenditure to be fully financed via **internal accruals**, maintaining a disciplined balance sheet. ## D. Long-term Strategy * **Market Opportunity:** Potential to capture long-term contracts in **regulated markets** as a major competitor exits the Ibuprofen space. * **Operational Excellence:** Strategic pivot toward **process automation** and diversification to insulate the business from geopolitical dynamism and market volatility. * **Portfolio Evolution:** Long-term roadmap emphasizes scaling key APIs and enhancing **integration capabilities** to build a sustainable growth platform.